Finland's Bioretec H1 revenue rises 12%, loss narrows

Bioretec Oy

13/08/2026 07:15

Overview
Finland-based medical device maker's H1 revenue grew 12% yr/yr
Company's H1 net loss and EBITDA loss narrowed compared to last year
Company raised €12.9 mln in rights issue and appointed new CFO

Outlook
Bioretec prioritizes disciplined execution and capital efficiency for 2026–2028 strategy
Company plans to invest in market presence and visibility across key markets
Bioretec focuses on expanding RemeOs platform and progressing near-term product pipeline

Result Drivers
GEOGRAPHIC SALES GROWTH - Co said H1 revenue growth was driven by 133% yr/yr increase in the U.S. and 63% in Europe
DIVERSIFIED CUSTOMER BASE - Co attributed improved adjusted sales margin to a broader mix of customers and distribution partners across key markets
COST DISCIPLINE - Co said focus on cost discipline and operational efficiency contributed to results

Company press release: ID:nWkr88fz4X

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 2.32 mln
 
H1 Adjusted Loss Per Share
 
EUR 0.01
 
H1 Loss Per Share
 
EUR 0.003
 
H1 Net Loss
 
EUR 4.68 mln
 
H1 EBITDA
 
-EUR 3.63 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Bioretec Oy is €0.03, about 7.1% below its August 12 closing price of €0.03

Reuters Recommended Reads
Aug 13 - Germany's Ottobock H1 core revenue rises 7.7%, EBITDA margin improves
Aug 13 - Switzerland's Kuros Biosciences swing to H1 profit as revenue jumps
Aug 12 - Israel's IceCure Medical H1 revenue rises on higher system, probe sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)